News | February 20, 2024
Briefs: IOL Chemicals and Pharmaceuticals and Auro Peptides
IOL Chemicals and Pharmaceuticals’ product approved by CDE of NMPA, China
IOL Chemicals and Pharmaceuticals’ product approved by CDE of NMPA, China
The company recently received CEP certificate approval for Losartan Potassium by EDQM
EBITDA for Q2 FY24 at Rs. 71.2 crore as compared to Rs. 79.9 crore QoQ
IOL Chemicals and Pharmaceuticals has reported total income of Rs. 570.24 crores during the period ended June 30, 2023
The 'A+' rating reflects IOL's robust business model, diversified product portfolio
The certification issued by the EDQM verifies the compliance of pharmaceutical substances
Net profit for FY23 at Rs. 140 crore as compared to Rs. 166 crore in FY22
Vikas Vij has been appointed as Chief Executive Officer (CEO) of the company
The company completed paracetamol capacity expansion by 1,800 MTPA and the company is now focusing on frugal manufacturing practices to reduce raw material cost and expand margins
The National Institute of Pharmacy and Nutrition, Hungary has issued 'Certificate of GMP Compliance of Manufacturer' for IOL Chemicals and Pharmaceuticals Limited's products.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)